Shopping Cart 0
Cart Subtotal
AED 0

Chiesi Farmaceutici SpA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 0

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 0

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 0

Details

Summary

Chiesi Farmaceutici SpA (Chiesi) researches, develops, produces and commercializes novel medicines with focus on respiratory, neonatology, rare disease and special care therapeutic areas. The company provides products for the treatment of chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, ankylosing spondylitis, hypertension, percutaneous coronary intervention, apnoea of prematurity, respiratory distress syndrome (RDS), lipoprotein lipase deficiency (LPLD), limbal stem cell deficiency (LSCD), inflammatory bowel diseases and renal and liver failure-solid organ transplant (SOT). The company operates production sites in Parma, Italy; Blois, France; and Santana De Parnaiba, Brazil; and carries out research and development (R&D) activities at its new R&D center in Parma and at laboratories in Paris, Chippenham (UK), Cary (US), Lidingo (Sweden) and Hillerod (Denmark). Chiesi is headquartered in Parma, Italy.

Chiesi Farmaceutici SpA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 14

Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 15

Atopix Acquires OC459 and CRTH2 Antagonists from Oxagen 17

Venture Financing 19

Atopix Therapeutics Raises Additional Funds through Venture Financing 19

Atopix Therapeutics Raises Funds through Extended Series A Financing 20

Atopix Raises USD5.7 Million in Series A Financing Round 21

Private Equity 22

Charterhouse Capital Partners Acquires Doc Generici For USD 424 Million 22

Partnerships 24

Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 24

Charles River Laboratories International Expands its Agreement with Chiesi Farmaceutici 25

Aptuit Enters into Agreement with Chiesi Farmaceutici 26

Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 27

Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici for Bronchitol in US 28

Chiesi Farmaceutici Enters into Agreement With University College London 29

Pharmathen Enters Into Co-Promotion Agreement With Chiesi For Nebulized Inhaled Corticosteroid 30

Activaero Enters Into Research Agreement With Chiesi Farmaceutici 31

Eddingpharm Forms Joint Venture With Chiesi Farmaceutici 32

Veloxis Pharma Enters Into Distribution Agreement With Chiesi Farmaceutici For LCP-Tacro 33

Licensing Agreements 34

Chiesi Farmaceutici Expands Licensing Agreement with Protalix 34

Chiesi Farmaceutici Enters into Licensing Agreement with Veloxis Pharma 36

Palladio Biosciences Enters into Agreement with Chiesi USA 37

Aratana Therapeutics Enters into Licensing Agreement with Atopix Therapeutics for CRTH2 38

Cornerstone Therapeutics Enters Into Licensing Agreement With Chiesi Farmaceutici For Bethkis 39

CereSpir Enters Into Licensing Agreement With Chiesi Farmaceutici For CHF 5074 40

Cornerstone Enters Into Licensing Agreement With Digestive Care For Pertzye 41

Asset Transactions 42

Laboratorio Reig Jofre Acquires Right for Heparin Sodium in Spain from Chiesi Espana 42

Neos Therapeutics Acquires Tussionex from Chiesi and Coating Place 43

Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 44

Acquisition 45

Chiesi Farmaceutici Acquires Atopix Therapeutics for USD79 Million 45

Chiesi Farmaceutici Completes Acquisition Of Remaining 42% Stake In Cornerstone Therapeutics For USD 255 Million 46

Chiesi Farmaceutici Acquires Zymenex from Sunstone Capital 48

Cornerstone Therapeutics Completes Acquisition Of EKR Therapeutics For Up To USD 150 Million 49

Cornerstone Therapeutics Acquires Pharma Company, Cardiokine 51

Chiesi Farmaceutici SpA-Key Competitors 52

Chiesi Farmaceutici SpA-Key Employees 53

Chiesi Farmaceutici SpA-Locations And Subsidiaries 54

Head Office 54

Other Locations & Subsidiaries 54

Recent Developments 57

Product News 57

11/20/2017: Protalix BioTherapeutics Announces Presentation to be made at the New Horizons in Fabry Disease Conference 57

11/13/2017: Protalix BioTherapeutics Receives Positive Opinion for Orphan Designation for PRX-102 for the Treatment of Fabry Disease in the European Union 58

09/07/2017: TRIBUTE study shows superiority of Chiesi's Trimbow (Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (GB)) over Ultibro (indacaterol/glycopyrronium) in reducing COPD exacerbations 59

06/01/2017: Protalix BioTherapeutics Announces FDA Approval to Operate its Current Facility as a Multi-Product Facility 60

05/29/2018: Chiesi Group has presented data at two international congresses on the role of its extrafine formulation ICS/LABA/LAMA vs LABA/LAMA in the treatment of COPD patients 61

05/20/2017: Trimbow is the first triple combination in a single inhaler for the treatment of COPD to receive positive opinion from the CHMP in Europe 63

05/09/2017: Protalix Announces FDA Investigational New Drug Clearance to Commence Once-Monthly Dosing Study of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease 64

04/04/2017: For the second time, Chiesi's extrafine fixed dose ICS/LABA/LAMA triple therapy earns a place in the pages of The Lancet, with the publication of Chiesi's TRINITY study 65

02/13/2017: Protalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium 2017 67

01/29/2018: Protalix BioTherapeutics to Participate in the 14th Annual WORLDSymposium 2018 68

Product Approvals 69

Jun 12, 2018: Chiesi and Holostem Announce FDA Orphan Drug Designation for GPLSCD01 for treatment of Limbal Stem Cell Deficiency (LSCD) 69

Jan 31, 2018: Protalix BioTherapeutics' pegunigalsidase alfa Receives Fast Track Designation from the U.S. Food and Drug Administration 70

Dec 27, 2017: Protalix BioTherapeutics' PRX-102 Granted Orphan Drug Designation by the European Commission 71

Oct 09, 2017: Trimbow is accepted for restricted use within NHS Scotland 72

Aug 24, 2017: NICE recommends Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells) for the treatment of moderate to severe limbal stem cell deficiency after eye burns 73

Jul 24, 2017: Chiesi Group receives the European Marketing Authorisation for Trimbow (inhaled corticosteroid / long-acting 2-agonist / long-acting muscarinic antagonist) 74

Clinical Trials 75

May 25, 2018: Protalix BioTherapeutics Announces Poster Presentation on Baseline Characteristics for Fabry Disease Patients Screened in the Phase III BALANCE Study of Pegunigalsidase Alfa at the 55th ERA-EDTA Congress 75

Nov 27, 2017: Protalix BioTherapeutics Presents Positive Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference 76

Aug 30, 2017: Inhalation Sciences: PreciseInhale achieves positive results in Chiesi tests 77

Apr 18, 2017: Protalix BioTherapeutics Announces New Preclinical Results Demonstrating a Positive Effect of pegunigalsidase alfa (PRX-102) on Small-fiber Neuropathy in Fabry Disease Models Compared to Commercially Available Enzyme Replacement Therapies 78

Appendix 79

Methodology 79

About GlobalData 79

Contact Us 79

Disclaimer 79


List Of Figure

List of Figures

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Chiesi Farmaceutici SpA, Deals By Therapy Area, 2012 to YTD 2018 9

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 14

Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 15

Atopix Acquires OC459 and CRTH2 Antagonists from Oxagen 17

Atopix Therapeutics Raises Additional Funds through Venture Financing 19

Atopix Therapeutics Raises Funds through Extended Series A Financing 20

Atopix Raises USD5.7 Million in Series A Financing Round 21

Charterhouse Capital Partners Acquires Doc Generici For USD 424 Million 22

Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 24

Charles River Laboratories International Expands its Agreement with Chiesi Farmaceutici 25

Aptuit Enters into Agreement with Chiesi Farmaceutici 26

Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 27

Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici for Bronchitol in US 28

Chiesi Farmaceutici Enters into Agreement With University College London 29

Pharmathen Enters Into Co-Promotion Agreement With Chiesi For Nebulized Inhaled Corticosteroid 30

Activaero Enters Into Research Agreement With Chiesi Farmaceutici 31

Eddingpharm Forms Joint Venture With Chiesi Farmaceutici 32

Veloxis Pharma Enters Into Distribution Agreement With Chiesi Farmaceutici For LCP-Tacro 33

Chiesi Farmaceutici Expands Licensing Agreement with Protalix 34

Chiesi Farmaceutici Enters into Licensing Agreement with Veloxis Pharma 36

Palladio Biosciences Enters into Agreement with Chiesi USA 37

Aratana Therapeutics Enters into Licensing Agreement with Atopix Therapeutics for CRTH2 38

Cornerstone Therapeutics Enters Into Licensing Agreement With Chiesi Farmaceutici For Bethkis 39

CereSpir Enters Into Licensing Agreement With Chiesi Farmaceutici For CHF 5074 40

Cornerstone Enters Into Licensing Agreement With Digestive Care For Pertzye 41

Laboratorio Reig Jofre Acquires Right for Heparin Sodium in Spain from Chiesi Espana 42

Neos Therapeutics Acquires Tussionex from Chiesi and Coating Place 43

Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 44

Chiesi Farmaceutici Acquires Atopix Therapeutics for USD79 Million 45

Chiesi Farmaceutici Completes Acquisition Of Remaining 42% Stake In Cornerstone Therapeutics For USD 255 Million 46

Chiesi Farmaceutici Acquires Zymenex from Sunstone Capital 48

Cornerstone Therapeutics Completes Acquisition Of EKR Therapeutics For Up To USD 150 Million 49

Cornerstone Therapeutics Acquires Pharma Company, Cardiokine 51

Chiesi Farmaceutici SpA, Key Competitors 52

Chiesi Farmaceutici SpA, Key Employees 53

Chiesi Farmaceutici SpA, Subsidiaries 54

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

Chiesi Farmaceutici SpA (Chiesi) researches, develops, produces and commercializes novel medicines with focus on respiratory, neonatology, rare disease and special care therapeutic areas. The company provides products for the treatment of chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, ankylosing spondylitis, hypertension, percutaneous coronary intervention, apnoea of prematurity, respiratory distress syndrome (RDS), lipoprotein lipase deficiency (LPLD), limbal stem cell deficiency (LSCD), inflammatory bowel diseases and renal and liver failure-solid organ transplant (SOT). The company operates production sites in Parma, Italy; Blois, France; and Santana De Parnaiba, Brazil; and carries out research and development (R&D) activities at its new R&D center in Parma and at laboratories in Paris, Chippenham (UK), Cary (US), Lidingo (Sweden) and Hillerod (Denmark). Chiesi is headquartered in Parma, Italy.

Chiesi Farmaceutici SpA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 14

Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 15

Atopix Acquires OC459 and CRTH2 Antagonists from Oxagen 17

Venture Financing 19

Atopix Therapeutics Raises Additional Funds through Venture Financing 19

Atopix Therapeutics Raises Funds through Extended Series A Financing 20

Atopix Raises USD5.7 Million in Series A Financing Round 21

Private Equity 22

Charterhouse Capital Partners Acquires Doc Generici For USD 424 Million 22

Partnerships 24

Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 24

Charles River Laboratories International Expands its Agreement with Chiesi Farmaceutici 25

Aptuit Enters into Agreement with Chiesi Farmaceutici 26

Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 27

Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici for Bronchitol in US 28

Chiesi Farmaceutici Enters into Agreement With University College London 29

Pharmathen Enters Into Co-Promotion Agreement With Chiesi For Nebulized Inhaled Corticosteroid 30

Activaero Enters Into Research Agreement With Chiesi Farmaceutici 31

Eddingpharm Forms Joint Venture With Chiesi Farmaceutici 32

Veloxis Pharma Enters Into Distribution Agreement With Chiesi Farmaceutici For LCP-Tacro 33

Licensing Agreements 34

Chiesi Farmaceutici Expands Licensing Agreement with Protalix 34

Chiesi Farmaceutici Enters into Licensing Agreement with Veloxis Pharma 36

Palladio Biosciences Enters into Agreement with Chiesi USA 37

Aratana Therapeutics Enters into Licensing Agreement with Atopix Therapeutics for CRTH2 38

Cornerstone Therapeutics Enters Into Licensing Agreement With Chiesi Farmaceutici For Bethkis 39

CereSpir Enters Into Licensing Agreement With Chiesi Farmaceutici For CHF 5074 40

Cornerstone Enters Into Licensing Agreement With Digestive Care For Pertzye 41

Asset Transactions 42

Laboratorio Reig Jofre Acquires Right for Heparin Sodium in Spain from Chiesi Espana 42

Neos Therapeutics Acquires Tussionex from Chiesi and Coating Place 43

Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 44

Acquisition 45

Chiesi Farmaceutici Acquires Atopix Therapeutics for USD79 Million 45

Chiesi Farmaceutici Completes Acquisition Of Remaining 42% Stake In Cornerstone Therapeutics For USD 255 Million 46

Chiesi Farmaceutici Acquires Zymenex from Sunstone Capital 48

Cornerstone Therapeutics Completes Acquisition Of EKR Therapeutics For Up To USD 150 Million 49

Cornerstone Therapeutics Acquires Pharma Company, Cardiokine 51

Chiesi Farmaceutici SpA-Key Competitors 52

Chiesi Farmaceutici SpA-Key Employees 53

Chiesi Farmaceutici SpA-Locations And Subsidiaries 54

Head Office 54

Other Locations & Subsidiaries 54

Recent Developments 57

Product News 57

11/20/2017: Protalix BioTherapeutics Announces Presentation to be made at the New Horizons in Fabry Disease Conference 57

11/13/2017: Protalix BioTherapeutics Receives Positive Opinion for Orphan Designation for PRX-102 for the Treatment of Fabry Disease in the European Union 58

09/07/2017: TRIBUTE study shows superiority of Chiesi's Trimbow (Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (GB)) over Ultibro (indacaterol/glycopyrronium) in reducing COPD exacerbations 59

06/01/2017: Protalix BioTherapeutics Announces FDA Approval to Operate its Current Facility as a Multi-Product Facility 60

05/29/2018: Chiesi Group has presented data at two international congresses on the role of its extrafine formulation ICS/LABA/LAMA vs LABA/LAMA in the treatment of COPD patients 61

05/20/2017: Trimbow is the first triple combination in a single inhaler for the treatment of COPD to receive positive opinion from the CHMP in Europe 63

05/09/2017: Protalix Announces FDA Investigational New Drug Clearance to Commence Once-Monthly Dosing Study of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease 64

04/04/2017: For the second time, Chiesi's extrafine fixed dose ICS/LABA/LAMA triple therapy earns a place in the pages of The Lancet, with the publication of Chiesi's TRINITY study 65

02/13/2017: Protalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium 2017 67

01/29/2018: Protalix BioTherapeutics to Participate in the 14th Annual WORLDSymposium 2018 68

Product Approvals 69

Jun 12, 2018: Chiesi and Holostem Announce FDA Orphan Drug Designation for GPLSCD01 for treatment of Limbal Stem Cell Deficiency (LSCD) 69

Jan 31, 2018: Protalix BioTherapeutics' pegunigalsidase alfa Receives Fast Track Designation from the U.S. Food and Drug Administration 70

Dec 27, 2017: Protalix BioTherapeutics' PRX-102 Granted Orphan Drug Designation by the European Commission 71

Oct 09, 2017: Trimbow is accepted for restricted use within NHS Scotland 72

Aug 24, 2017: NICE recommends Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells) for the treatment of moderate to severe limbal stem cell deficiency after eye burns 73

Jul 24, 2017: Chiesi Group receives the European Marketing Authorisation for Trimbow (inhaled corticosteroid / long-acting 2-agonist / long-acting muscarinic antagonist) 74

Clinical Trials 75

May 25, 2018: Protalix BioTherapeutics Announces Poster Presentation on Baseline Characteristics for Fabry Disease Patients Screened in the Phase III BALANCE Study of Pegunigalsidase Alfa at the 55th ERA-EDTA Congress 75

Nov 27, 2017: Protalix BioTherapeutics Presents Positive Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference 76

Aug 30, 2017: Inhalation Sciences: PreciseInhale achieves positive results in Chiesi tests 77

Apr 18, 2017: Protalix BioTherapeutics Announces New Preclinical Results Demonstrating a Positive Effect of pegunigalsidase alfa (PRX-102) on Small-fiber Neuropathy in Fabry Disease Models Compared to Commercially Available Enzyme Replacement Therapies 78

Appendix 79

Methodology 79

About GlobalData 79

Contact Us 79

Disclaimer 79


List Of Figure

List of Figures

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Chiesi Farmaceutici SpA, Deals By Therapy Area, 2012 to YTD 2018 9

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 14

Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 15

Atopix Acquires OC459 and CRTH2 Antagonists from Oxagen 17

Atopix Therapeutics Raises Additional Funds through Venture Financing 19

Atopix Therapeutics Raises Funds through Extended Series A Financing 20

Atopix Raises USD5.7 Million in Series A Financing Round 21

Charterhouse Capital Partners Acquires Doc Generici For USD 424 Million 22

Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 24

Charles River Laboratories International Expands its Agreement with Chiesi Farmaceutici 25

Aptuit Enters into Agreement with Chiesi Farmaceutici 26

Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 27

Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici for Bronchitol in US 28

Chiesi Farmaceutici Enters into Agreement With University College London 29

Pharmathen Enters Into Co-Promotion Agreement With Chiesi For Nebulized Inhaled Corticosteroid 30

Activaero Enters Into Research Agreement With Chiesi Farmaceutici 31

Eddingpharm Forms Joint Venture With Chiesi Farmaceutici 32

Veloxis Pharma Enters Into Distribution Agreement With Chiesi Farmaceutici For LCP-Tacro 33

Chiesi Farmaceutici Expands Licensing Agreement with Protalix 34

Chiesi Farmaceutici Enters into Licensing Agreement with Veloxis Pharma 36

Palladio Biosciences Enters into Agreement with Chiesi USA 37

Aratana Therapeutics Enters into Licensing Agreement with Atopix Therapeutics for CRTH2 38

Cornerstone Therapeutics Enters Into Licensing Agreement With Chiesi Farmaceutici For Bethkis 39

CereSpir Enters Into Licensing Agreement With Chiesi Farmaceutici For CHF 5074 40

Cornerstone Enters Into Licensing Agreement With Digestive Care For Pertzye 41

Laboratorio Reig Jofre Acquires Right for Heparin Sodium in Spain from Chiesi Espana 42

Neos Therapeutics Acquires Tussionex from Chiesi and Coating Place 43

Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 44

Chiesi Farmaceutici Acquires Atopix Therapeutics for USD79 Million 45

Chiesi Farmaceutici Completes Acquisition Of Remaining 42% Stake In Cornerstone Therapeutics For USD 255 Million 46

Chiesi Farmaceutici Acquires Zymenex from Sunstone Capital 48

Cornerstone Therapeutics Completes Acquisition Of EKR Therapeutics For Up To USD 150 Million 49

Cornerstone Therapeutics Acquires Pharma Company, Cardiokine 51

Chiesi Farmaceutici SpA, Key Competitors 52

Chiesi Farmaceutici SpA, Key Employees 53

Chiesi Farmaceutici SpA, Subsidiaries 54

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS